Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ INHA Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA576771
Description
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
The inhibin alpha subunit joins either the beta A or beta B subunit to form a pituitary FSH secretion inhibitor. Inhibin has been shown to regulate gonadal stromal cell proliferation negatively and to have tumor-suppressor activity. In addition, serum levels of inhibin have been shown to reflect the size of granulosa-cell tumors and can therefore be used as a marker for primary as well as recurrent disease. However, in prostate cancer, expression of the inhibin alpha-subunit gene was suppressed and was not detectable in poorly differentiated tumor cells. Furthermore, because expression in gonadal and various extragonadal tissues may vary severalfold in a tissue-specific fashion, it is proposed that inhibin may be both a growth/differentiation factor and a hormone.
Specifications
INHA | |
Polyclonal | |
Unconjugated | |
INHA | |
A inhibin subunit; A-inhibin subunit; AW555078; IHA; Inha; inhibin; inhibin alpha; inhibin alpha chain; inhibin alpha subunit | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
16322, 24504, 3623 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.2 | |
P05111, P17490, Q04997 | |
INHA | |
Recombinant full length Human INHA. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction